Aromatase inhibitors (AIs) which target aromatase, an enzyme involved in the conversion of androgen into estrogen in the body, is a commonly used therapeutic option as hormone treatment (HT) [4, 5, 6, 7, 8] in patients with ERα‐positive breast cancers. This evidence concerns the gene CYP19A1 and breast carcinoma.